Imtesty......some good rambling actually.

The thing with RVX and apabetalone is that stellar results in a lab, and then in very small trials, that then get beautifully published in journals, are not materializing or translating the same way in larger trials. So, the market becomes skeptical and the notion of being 'years ahead' of everyone else comes down to .........ahead of what exactly?

I'm not sure that a Covid trial comprised of 100 unfortunate souls will bring the results everyone is hoping for unless the data is very very compelling.  My concern is that in the absence of that we risk even further skepticism or a scenario that may in fact limit the company's ability to finance another BoM trial.

Let's hope the data on this Covid trial turns some heads in a good way.  We really need it.